These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 19151457)

  • 21. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice.
    Pitt B
    Heart; 2009 Aug; 95(15):1205-8. PubMed ID: 19401281
    [No Abstract]   [Full Text] [Related]  

  • 23. The hazards of dual renin-angiotensin blockade in chronic kidney disease.
    Ku E; Park J; Vidhun J; Campese V
    Arch Intern Med; 2009 Jun; 169(11):1015-8. PubMed ID: 19506167
    [No Abstract]   [Full Text] [Related]  

  • 24. The evolution of angiotensin blockade in the management of cardiovascular disease.
    Nantel P; René de Cotret P
    Can J Cardiol; 2010 Dec; 26 Suppl E():7E-13E. PubMed ID: 21620285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function.
    Qian C; Schoemaker RG; van Gilst WH; Roks AJ
    Clin Sci (Lond); 2009 Feb; 116(4):301-14. PubMed ID: 19138171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Q: Is an ACE inhibitor plus an ARB more effective than either drug alone?
    Messerli FH; Yuzefpolskaya M
    Cleve Clin J Med; 2009 Dec; 76(12):693-6. PubMed ID: 19952293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Renin Report.
    Sica DA; Ichihara A
    J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):247-51. PubMed ID: 17347934
    [No Abstract]   [Full Text] [Related]  

  • 28. Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved.
    Probstfield J
    J Fam Pract; 2009 Jun; 58(6 Suppl):S1-8. PubMed ID: 19508849
    [No Abstract]   [Full Text] [Related]  

  • 29. [Angiotensin II antagonists: new therapeutic perspectives].
    Leggio M; Del Sindaco D; Sgorbini L; Cicone E; Leggio F
    Clin Ter; 2003; 154(6):405-14. PubMed ID: 14994521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers.
    Berl T
    Nephrol Dial Transplant; 2008 Aug; 23(8):2443-7. PubMed ID: 18467376
    [No Abstract]   [Full Text] [Related]  

  • 31. Inhibition of the renin-angiotensin system in cardiovascular protection: Is it important to watch your C'ARB' intake?
    Strauss MH; Verma S
    Can J Cardiol; 2005 May; 21(7):577-80. PubMed ID: 15940355
    [No Abstract]   [Full Text] [Related]  

  • 32. Dual renin-angiotensin system blockade and kidney disease.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Pfeffer MA
    J Am Coll Cardiol; 2009 Jul; 54(3):278-9; author reply 279-80. PubMed ID: 19589445
    [No Abstract]   [Full Text] [Related]  

  • 33. Angiotensin II receptor blockers: current perspective.
    Agrawal V; Manohar G; Kasliwal RR
    J Assoc Physicians India; 2003 Jul; 51():706-13. PubMed ID: 14621043
    [No Abstract]   [Full Text] [Related]  

  • 34. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease.
    Onuigbo MA
    Nephrol Dial Transplant; 2010 Apr; 25(4):1344-5. PubMed ID: 20037177
    [No Abstract]   [Full Text] [Related]  

  • 35. Introduction. The cardiovascular continuum in the 21st century: renin-angiotensin system blockade, the cardiovascular continuum in the 21st century.
    Probstfield JL; Weber MA
    Am J Cardiol; 2010 Jan; 105(1 Suppl):1A-2A. PubMed ID: 20102967
    [No Abstract]   [Full Text] [Related]  

  • 36. ARBs or ACEIs, that is the question.
    Ishigami T; Uchino K; Umemura S
    Hypertens Res; 2006 Nov; 29(11):837-8. PubMed ID: 17345782
    [No Abstract]   [Full Text] [Related]  

  • 37. Preventing and reversing target organ damage by treatment of the renin-angiotensin system.
    Krakoff LR; Rajasekharaiah V
    Mt Sinai J Med; 1998 Mar; 65(2):125-32. PubMed ID: 9520516
    [No Abstract]   [Full Text] [Related]  

  • 38. The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
    Pierson CA; Epstein BJ; Roberts ME
    J Am Acad Nurse Pract; 2008 Nov; 20(11):529-38. PubMed ID: 19128336
    [No Abstract]   [Full Text] [Related]  

  • 39. "As time goes by": angiotensin II-mediated transactivation of the EGF receptor comes of age.
    Wolf G
    Nephrol Dial Transplant; 2005 Oct; 20(10):2050-3. PubMed ID: 16166749
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of the renin-angiotensin system in cardiovascular disease.
    Cohn JN
    Cardiovasc Drugs Ther; 2010 Aug; 24(4):341-4. PubMed ID: 20454841
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.